arrow
S

Steven N. Goodman

Stanford University
H指数:97
被引数:4.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Registration and reporting of clinical trials affiliated with California universities and with primary completion date from 2014 to 2017

加利福尼亚大学附属临床试验的注册和报告,其主要完成日期为2014年至2017年

2025-12-010
PRE
CONSORT 2025 Statement: Updated Guideline for Reporting Randomized Trials

CONSORT 2025声明:随机试验报告更新指南

2025-06-102
PRE
The Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Primary Staging of Selected Renal Tumours: Initial Experience in a Multicentre Cohort
2024-09-012
OAAI
Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials (vol 12, 2349, 2021)

羟氯喹和氯喹在新型冠状病毒肺炎中的死亡率结果: 一项随机试验的国际合作荟萃分析 (第12卷,2349,2021卷)

2024-02-050
OAAI
Clinical impact of Prostate-Specific Membrane Antigen Positron Emission Tomography (PET) on intensification or deintensification of advanced renal cell carcinoma management
2023-08-183
OAAI
Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials

新型冠状病毒肺炎恢复期血浆治疗与死亡率的关系: 一项随机临床试验的协作系统评价和荟萃分析

2021-11-2050
OAAI
Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials (vol 12, 2349, 2021)

羟氯喹和氯喹在新型冠状病毒肺炎中的死亡率结果: 一项随机试验的国际合作荟萃分析 (第12卷,2349,2021卷)

2021-05-1411
OAAI
Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials

羟氯喹和氯喹治疗新型冠状病毒肺炎的死亡率结果: 一项随机试验的国际合作荟萃分析

2021-04-15198
OAAI
Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19 A Systematic Review and Meta-analysis

新型冠状病毒肺炎患者恢复期血浆治疗与临床结局相关性的系统评价和Meta分析

2021-03-23186
OA